Patents by Inventor Michael D. Gunn
Michael D. Gunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11684662Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.Type: GrantFiled: July 11, 2021Date of Patent: June 27, 2023Assignee: Duke UniversityInventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
-
Publication number: 20220031827Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.Type: ApplicationFiled: July 11, 2021Publication date: February 3, 2022Applicant: Duke UniversityInventors: John H Sampson, Duane A Mitchell, Kristen A Batich, Michael D Gunn
-
Patent number: 11071777Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.Type: GrantFiled: April 19, 2018Date of Patent: July 27, 2021Assignee: Duke UniversityInventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
-
Publication number: 20190381158Abstract: Methods of generating an autologous cellular vaccine comprising monocytes or neutrophils and an antigenic polypeptide or nucleotide encoding the antigenic polypeptide are provided. The antigen-loaded cell-based vaccine compositions made using these methods are also provided. Methods of using the antigen-loaded cell-based vaccine compositions are also provided and these vaccines may be used to treat cancer. Kits for carrying out the methods described herein are also provided.Type: ApplicationFiled: February 3, 2017Publication date: December 19, 2019Applicant: Duke UniversityInventor: Michael D. Gunn
-
Publication number: 20190060265Abstract: A method of treating acute lung injury (ALI) in a patient suspected of having ALI is disclosed. The method includes administering to the patient a therapeutically effective amount of an inducible nitric oxide synthase (iNOS) inhibitor.Type: ApplicationFiled: February 23, 2018Publication date: February 28, 2019Inventor: Michael D. Gunn
-
Publication number: 20180236054Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.Type: ApplicationFiled: April 19, 2018Publication date: August 23, 2018Applicant: Duke UniversityInventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
-
Patent number: 9974848Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.Type: GrantFiled: November 14, 2014Date of Patent: May 22, 2018Assignee: Duke UniversityInventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn
-
Patent number: 9901560Abstract: A method of treating acute lung injury (ALI) in a patient suspected of having ALI is disclosed. The method includes administering to the patient a therapeutically effective amount of an inducible nitric oxide synthase (iNOS) inhibitor.Type: GrantFiled: December 14, 2016Date of Patent: February 27, 2018Assignee: Duke UniversityInventor: Michael D. Gunn
-
Publication number: 20170165216Abstract: A method of treating acute lung injury (ALI) in a patient suspected of having ALI is disclosed. The method includes administering to the patient a therapeutically effective amount of an inducible nitric oxide synthase (iNOS) inhibitor.Type: ApplicationFiled: December 14, 2016Publication date: June 15, 2017Inventor: Michael D. Gunn
-
Publication number: 20160271240Abstract: Pre-conditioning a vaccine site with a potent recall antigen such as tetanus/diphtheria (Td) toxoid can significantly improve the lymph node homing and efficacy of tumor antigen-specific DC vaccines. Patients given Td had enhanced DC migration bilaterally and significantly improved survival. In mice, Td pre-conditioning also enhanced bilateral DC migration and suppressed tumor growth in a manner dependent on the chemokines CCL3 and CCL21 and Td-activated CD4+ T cells. Interference with any component of this axis markedly reduced Td-mediated DC migration and antitumor responses. Our clinical studies and corroborating investigations in mice suggest that pre-conditioning with a potent recall antigen represents a viable strategy to increase DC homing to lymph nodes and improve antitumor immunotherapy.Type: ApplicationFiled: November 14, 2015Publication date: September 22, 2016Applicant: Duke UniversityInventors: John H. Sampson, Duane A. Mitchell, Kristen A. Batich, Michael D. Gunn